Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Endocrinology and Metabolism ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prevalence, risk factors, and pathophysiology of nonalcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS).Biomedicines. 2022; 10: 131
- Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.J Endocrinol Invest. 2017; 40: 1279-1288
- Update on PCOS: consequences, challenges, and guiding treatment.J Clin Endocrinol Metab. 2021; 106: e1071-e1083
- Polycystic ovary syndrome.Nat Rev Dis Primer. 2016; 2: 16057
- Polycystic ovary syndrome.Obstet Gynecol. 2018; 132: 321-336
- Scientific Statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome.Endocr Rev. 2015; 36: 487-525
- Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism.Front Horm Res. 2013; 40: 22-27
- Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.Nat Rev Endocrinol. 2011; 7: 219-231
- Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome.Nat Med. 2019; 25: 1894-1904
- Heritability of polycystic ovary syndrome in a dutch twin-family study.J Clin Endocrinol Metab. 2006; 91: 2100-2104
- Endocrine-disrupting chemicals: an endocrine society scientific statement.Endocr Rev. 2009; 30: 293-342
- Environmental determinants of polycystic ovary syndrome.Fertil Steril. 2016; 106: 16-24
- Causes and consequences of polycystic ovary syndrome: insights from mendelian randomization.J Clin Endocrinol Metab. 2022; 107: e899-e911
- Hepatic manifestations of women with polycystic ovary syndrome.Best Pract Res Clin Obstet Gynaecol. 2016; 37: 119-128
- Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease.J Steroid Biochem Mol Biol. 2019; 194: 105445
- Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women: weight gain and BMI in PCOS.Obesity. 2013; 21: 1526-1532
- Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population.Ann Hepatol. 2020; 19: 251-257
- Nonalcoholic fatty liver disease and polycystic ovary syndrome.World J Gastroenterol. 2014; 20: 8351-8363
- A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis.Reprod Health. 2018; 15: 77
- The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association.Hepatology. 2012; 55: 2005-2023
- Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings.Endocr Pract. 2005; 11: 319-324
- Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis.JGH Open. 2021; 5: 434-445
- Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.Hum Reprod. 2018; 33: 1602-1618
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril. 2004; 81: 19-25
- A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol. 2020; 73: 202-209
- Ultrasound-based techniques for the diagnosis of liver steatosis.World J Gastroenterol. 2019; 25: 6053-6062
- Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology. 2019; 156: 1717-1730
- A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.Hepatology. 2010; 52: 79-104
- Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention.Trends Cardiovasc Med. 2020; 30: 399-404
- Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2004; 89: 5454-5461
- Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis.Can Med Assoc J. 2013; 185: E115-E120
- Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies.Hum Reprod Update. 2012; 18: 638-651
- Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study.J Womens Health. 2015; 24: 299-307
- Polycystic ovary syndrome.Lancet. 2007; 370: 685-697
- Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology. 2015; 149: 367-378.e5
- Treatment of NAFLD with diet, physical activity and exercise.J Hepatol. 2017; 67: 829-846
- Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis: Meta-analysis: insulin sensitizers for NASH.Aliment Pharmacol Ther. 2010; 32: 1211-1221
- Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis.JAMA Intern Med. 2017; 177: 633
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Gut. 2017; 66: 180-190
- Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial.Diabetes Obes Metab. 2018; 20: 215-218
- Vitamin E and the risk of prostate cancer: the selenium and Vitamin E cancer prevention trial (SELECT).JAMA. 2011; 306: 1549
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.N Engl J Med. 2010; 362: 1675-1685
- Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.Gastroenterology. 2008; 135: 1176-1184
- A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med. 2006; 355: 2297-2307
- Rosiglitazone for Nonalcoholic Steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial.Gastroenterology. 2008; 135: 100-110
- The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial.Ther Adv Gastroenterol. 2009; 2: 157-163
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial.J Hepatol. 2016; 65: 369-376
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.Hepatology. 2010; 52: 472-479
- Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.Hepatology. 2011; 54: 1610-1619
Article info
Publication history
Published online: March 15, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
